Treatment and prophylaxis of relapse of Plasmodium vivax malaria
Adult: 25 mg once daily for 7 days. To be used in comjunction with chloroquine.
                                            | 
                                         
Indications and Dosage
                                             
                                            
Oral 
                                        Treatment and prophylaxis of relapse of Plasmodium vivax malaria Adult: 25 mg once daily for 7 days. To be used in comjunction with chloroquine. 
                                             | 
                                
| 
                                         
Contraindications
                                             
                                            
Rheumatoid arthritis; systemic lupus erythematosus. Co-administration of drugs known to cause haemolysis.
                                             
                                         | 
                                
| 
                                         
Special Precautions
                                             
                                            
Exercise caution while administering bulaquine to patients suffering from G6PD deficiency. Pregnancy and lactation, children.
                                             
                                         | 
                                
| 
                                         
Drug Interactions
                                             
                                            
Specific studies with other drugs have not been undertaken except with chloroquine where it was concurrently used in the phase II/III clinical trials without any adverse effects. 
                                         | 
                                
| 
                                         
Action
                                             
                                            
Description:  
                                        Mechanism of Action: Bulaquine is a new generation of 8-aminoqinoline derivative antimalarial used in managing P. vivax infection. It reportedly inhibits protein synthesis in protozoa and polymerization of amino acids by the plasmodia. When co-administered with chloroquine, malarial is treated witho significant relapse episodes. Compared to primaquine, it requires lesser treatment days and it has better tolerance profile in patients with G6PD (G6PDH) deficiency.  | 
                                
| 
                                         
MIMS Class
                                             
                                            
                                         |